Format

Send to

Choose Destination
J Am Coll Cardiol. 2016 Oct 25;68(17):1898-1907. doi: 10.1016/j.jacc.2016.07.781.

The Changing Landscape of Randomized Clinical Trials in Cardiovascular Disease.

Author information

1
Department of Medicine and Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina. Electronic address: schuyler.jones@duke.edu.
2
Department of Medicine and Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina.
3
TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
4
Division of Clinical Epidemiology, Department of Epidemiology and Biostatistics, University of California, San Francisco, California.
5
Department of Medicine, Stanford University School of Medicine, Stanford, California.
6
Departments of Medicine and Pediatrics, Vanderbilt University, Nashville, Tennessee.
7
American College of Cardiology, Washington, DC.
8
Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado.

Abstract

Large randomized clinical trials in cardiovascular disease have proliferated over the past 3 decades, with results that have influenced every aspect of cardiology practice. Despite these advances, there remains a substantial need for more high-quality evidence to inform cardiovascular clinical practice, given the increasing prevalence of cardiovascular disease around the world. Traditional clinical trials are increasingly challenging due to rising costs, increasing complexity and length, and burdensome institutional and regulatory requirements. This review will examine the current landscape of cardiovascular clinical trials in the United States, highlight recently conducted registry-based clinical trials, and discuss the potential attributes of the recently launched pragmatic clinical trial by the Patient-Centered Outcomes Research Institute's National Patient-Centered Clinical Research Network, called the ADAPTABLE (Aspirin Dosing: A Patient-centric Trial Assessing the Benefits and Long-term Effectiveness) trial.

KEYWORDS:

Patient-Centered Outcomes Research Institute; aspirin; coronary artery disease; pragmatic clinical trial

PMID:
27765193
DOI:
10.1016/j.jacc.2016.07.781
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center